Last Updated : September 18, 2017
Details
FilesGeneric Name:
Nivolumab
Project Status:
Complete
Therapeutic Area:
Squamous Cell Carcinoma of Head and Neck (SCCHN)
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0095-000
NOC Status at Filing:
Pre NOC
Strength:
40mg and 100mg single-use vials
Tumour Type:
Head and Neck
Indications:
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Funding Request:
For the treatment of recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) after platinum-based therapy in adults
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : September 18, 2017